David Seaburg

Director

David Seaburg currently serves as Chair of the Board’s Strategic Review Committee and was previously a director from August 2018 to August 2019. Mr. Seaburg served as PolarityTE’s Chief Executive Officer from April 2020 through August 2021, President of Corporate Development from January 2019 to August 2019. During Mr. Seaburg’s tenure in management, the Company completed several significant restructuring initiatives, primarily focused on reducing costs, enhancing sales of SkinTE® when it was previously marketed as a 361 HCT/P, and preparing PolarityTE for the changes that would be required from a regulatory perspective for SkinTE following the conclusion of FDA’s period of enforcement discretion for 361 HCT/Ps in May 2021. Prior to PolarityTE, Mr. Seaburg spent roughly 25 years of his career at Cowen, Inc., a leading healthcare franchise in equities research, sales and investment banking. He was Managing Director, Head of Sales Trading and a member of the Cowen’s Equity Operating Committee, where he cultivated and led teams operating across multiple disciplines and specialties, leveraging human capital to drive the organization’s success. Over the course of his tenure, he interacted with thousands of healthcare investors and corporate management teams. Mr. Seaburg was also a CNBC Fast Money Contributor, where he provided regular on-air market commentary for the network.